PTHS logo

PELTHOS THERAPEUTICS INC

PTHSNYSE AMERICAN
πŸ† #4475 by market capEarnings Mar 17US Equity
$6.77β–Ό $0.04 (βˆ’0.66%)
Market closed Β· at close
πŸ””
Track PTHS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.7%
7dβ–Ό 7.1%
14dβ–Ό 28.9%
30dβ–Ό 60.4%
ytdβ–Ό 77.1%
1yβ–Ό 74.3%
🏦Market Cap
$27M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
78.6%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$6.76 – $6.87
52-Week Range
$6.02 – $32.51
Volume (shares)
1,622
Avg Volume (shares)
β€”
Shares Outstanding
3.9M
Next Earnings
2027-03-17

Fundamentals Snapshot

Annual Revenue
$17M
Last Q Revenue
$15M
P/E Ratio
β€”
P/S Ratio
0.6x
EPS (TTM)
$-21.82
Dividend Yield
β€”
Dilution (1yr)
+429.3%
PTHS logo

PELTHOS THERAPEUTICS INC

PTHS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17M
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$32Mβ–² +328.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$23Mβ–² +291.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.2Mβ–² +429.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$17Mβ–Ό βˆ’$15M YoY
StockOtter Β· stockotter.space

About PELTHOS THERAPEUTICS INC

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.